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Abstract
Drosophila tracheal fusion cells play multiple important roles in guiding and facilitating tracheal
branch fusion. Mechanistic understanding of how fusion cells function during development requires
deciphering their transcriptional circuitry. In this paper, three genes with distinct patterns of fusion
cell expression were dissected by transgenic analysis to identify the cis regulatory modules that
mediate their transcription. Bioinformatic analysis involving phylogenetic comparisons coupled with
mutational experiments were employed. The dysfusion bHLH-PAS gene was shown to have two
fusion cell cis-regulatory modules; one driving initial expression and another autoregulatory module
to enhance later transcription. Mutational dissection of the early module identified at least four
distinct inputs, and included putative binding sites for ETS and POU homeodomain proteins. The
ETS transcription factor Pointed mediates the transcriptional output of the branchless/breathless
signaling pathway, suggesting that this pathway directly controls dysfusion expression. Fusion cell
cis-regulatory modules of CG13196 and CG15252 require two Dysfusion:Tango binding sites, but
additional sequences modulate the breadth of activation in different fusion cell classes. These results
begin to decode the regulatory circuitry that guides transcriptional activation of genes required for
fusion cell morphogenesis.
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1. Introduction
The Drosophila tracheal system is derived from an array of segmentally-repeated clusters of
precursor cells. After the tracheal precursor cells divide and invaginate, they extend branches
(Manning and Krasnow, 1993). Most branches in each metamere grow towards branches from
neighboring segments, and then fuse to form the mature tracheal tree (Samakovlis et al.,
1996). Each branch fusion event is mediated by two specialized fusion cells, one on each
branch, that recognize each other. During branch migration, the fusion cells extend filopodia
that likely sense guidance cues and steer the branch to its target. The opposing fusion cells
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recognize and adhere to each other, leading to branch fusion. After fusion, the fusion cells
undergo a sequence of morphological changes leading to a connected tracheal tubule system
(Lee and Kolodziej, 2002). Fusion cell development is characterized by transcriptional
changes. These changes include both the upregulation and downregulation of fusion cell-
expressed genes. Two transcription factors present in fusion cells are the Dysfusion (Dys)
bHLH-PAS protein (Jiang and Crews, 2003; Jiang and Crews, 2006) and the Escargot (Esg)
zinc finger protein (Samakovlis et al., 1996; Tanaka-Matakatsu et al., 1996). Phenotypically,
both esg and dys promote tracheal fusion and inhibit branching, although dys is downstream
of esg and requires esg function for fusion cell expression in all branches, except the dorsal
trunk (DT). In this paper, we describe a detailed analysis of multiple tracheal fusion cell cis-
regulatory modules (CRMs) that are regulated in diverse ways. The molecular dissection of
fusion cell CRMs provides insight into the regulation of fusion cell development, and also
provides fusion cell-specific Gal4 lines useful for the purification and genetic analysis of fusion
cells.
The Dys protein is one of four Drosophila bHLH-PAS proteins that function in various aspects
of tracheal development. The Trachealess (Trh) protein acts as a master regulator of tracheal
development and is expressed in all tracheal cells (Isaac and Andrew, 1996; Wilk et al.,
1996). Trh requires the Ventral veins lacking (Vvl, or Drifter) coactivator protein to activate
tracheal gene expression (Zelzer and Shilo, 2000), although Vvl may regulate expression of
some tracheal genes in the absence of Trh (Boube et al., 2000). During tracheal fusion, the Trh
protein is downregulated in fusion cells by a dys-dependent, post-transcriptional mechanism
(Jiang and Crews, 2006), in which the Archipelago protease degrades Trh (Mortimer and
Moberg, 2007). The Similar (Sima) protein controls tracheal branching in response to hypoxia
(Lavista-Llanos et al., 2002; Nambu et al., 1996). All three proteins: Dys, Sima, and Trh, utilize
the Tango (Tgo) bHLH-PAS protein as a heterodimerization partner (Jiang and Crews, 2003;
Jiang and Crews, 2007; Sonnenfeld et al., 1997). Dys is an important regulator of fusion cell
transcription that is required for fusion cell recognition, adhesion, and potentially other
functions involved in fusion cell morphogenesis. Previously, we identified 4 genes,
CG13196, CG15252, members only (mbo), and shotgun (shg), whose transcription is
dependent on Dys function (Jiang and Crews, 2006), and showed that CG13196 is a direct
target of Dys:Tgo (Jiang and Crews, 2007).
Employing S2 cell transient transfection approaches, we demonstrated that Dys:Tgo efficiently
binds multiple asymmetric E-Box sequences, including ACGTG, GCGTG, and TCGTG (Jiang
and Crews, 2007), a result confirmed by in vitro biochemical approaches (Ooe et al., 2007).
This promiscuous DNA binding specificity is evolutionarily-conserved, as the human Dys
ortholog, NXF/Npas4, binds the same DNA sequences (Jiang and Crews, 2007; Ooe et al.,
2004; Ooe et al., 2007). We identified a 1 kb upstream fragment of CG13196 that contained
multiple TCGTG sequences, as well as ACGTG and GCGTG motifs. Mutational studies in
vivo revealed that only the TCGTG sequences are required in vivo (Jiang and Crews, 2007).
The importance of the TCGTG motifs was reinforced when a transgenic reporter containing a
promoter fused to multimerized TCGTG sequences was shown to be expressed in fusion cells.
Nevertheless, the generality of TCGTG sequences and fusion cell expression remains
unknown, as do the identities of additional co-regulatory proteins and cis-control sequences
that mediate fusion cell gene expression.
In this paper, we analyzed 3 genes with diverse patterns of fusion cell expression: (1) the dys
gene, which is expressed early in fusion cell development, (2) CG13196, which is a Dys target
gene expressed in all fusion cells, and (3) CG15252, which is a Dys target gene expressed only
in DT fusion cells. These studies contribute to an understanding of how dys fusion cell
expression is regulated, as well as conserved features of Dys-dependent regulation. CRMs that
drive fusion cell expression were identified for each gene using transgenic approaches. These
Jiang et al. Page 2













fragments of DNA were then scanned for phylogenetically-conserved sequence motifs. Such
motifs usually consist of DNA sequences between 4 and 20 bp, and are binding sites for
transcription factors. Conserved and repeated sequences, including putative Dys:Tgo binding
sites, were identified and their significance tested by in vitro mutagenesis and in vivo transgenic
analysis. In this manner, we identified a number of essential cis-regulatory elements that are
required for fusion cell expression. Other than Dys:Tgo binding sites, we did not identify
required sequences that were repeated in other fusion cell CRMs, suggesting that multiple
distinct regulatory mechanisms are utilized to activate each gene.
2. Results
2.1. Embryonic dys expression is regulated by diverse cis-regulatory sequences
The dys gene is expressed in multiple embryonic cell types beginning at stage 12, including
tracheal fusion cells, a subset of brain cells, epidermal leading edge cells, the foregut atrium,
hindgut, and anal pad (Jiang and Crews, 2003). We decided to explore the dys regulatory
sequences for multiple reasons: (1) dys is expressed relatively early in fusion cells and
expression is maintained throughout embryogenesis; is this due to a single CRM or multiple
temporally-distinct CRMs? (2) Similarly, does each branch type with fusion cells: dorsal
branch (DB), DT, lateral trunk (LT), and ganglionic branch (GB), have distinct CRMs for
fusion cell expression? (3) As dys expression is genetically-dependent on esg in all fusion cells,
except DT and possibly, LT (further suggesting branch-specific inputs to dys expression)
(Jiang and Crews, 2003), is dys a direct target of Esg? (4) Does dys fusion cell expression share
similar transcriptional inputs or CRMs that control dys expression in other tissues? (5) dys
fusion cell-specific fragments would be useful as a Gal4 line for analyzing fusion cell
development and function, and for purification of fusion cells to be used in biochemical or in
vitro studies.
To identify CRMs that control dys fusion cell expression, we examined 1–4 kb size fragments
of DNA from the 5′ flanking region and introns 1 and 2 using germline transformation (Fig.
1A). Fragments were PCR-amplified and cloned into either the pH-Stinger P-element vector
(B2.7, C1.7) or into the pMintGate ΦC31 vector (A3.8, D1.4, E3.8, F3.8; Supplementary Fig.
1). Both vectors contain a nuclear GFP reporter gene. The pMintGate transgenes were all
introduced into the attP2 site at 68A1-B2. Six transgenic reporter fly strains testing fragments
A3.8, B2.7, C1.7, D1.4, E3.8, and F3.8 were generated and the embryonic expression of
GFP analyzed. Immunostaining with anti-Dys was used to identify Dys+ cells. The A3.8
fragment drove GFP expression only in a subset of Dys− ectodermal cells (Fig 1B). This
expression is likely due to sequences in the pMintGate vector or the integration site of the
transgene, since they were commonly observed in pMintGate transformants. The B2.7
fragment drove GFP expression in all tracheal fusion cells, including those from DB, DT, LT,
and GB (Fig. 1C), as well as leading edge cells. The presence of GFP in fusion cells was
demonstrated by overlap with anti-Dys stained cells (Fig. D–F). The dynamics of B2.7 GFP
expression (Supplementary Fig. 2A-I; P155, a B2.7 derivative is shown) is consistent with
expression of endogenous dys from stages 12 through 17.
Expression in all tracheal fusion cells was also observed with the C1.7 fragment (Fig. 1G).
However, C1.7 fusion cell expression was only observed from stages 14–17 (Supplementary
Fig. 2J-O; T523, a C1.7 derivative is shown). These results indicated that the dys gene has at
least two independent CRMs, both in the 5′-flanking region, that control fusion cell expression
in temporally distinct ways. The C1.7 fragment overlaps with B2.7 by 20 bp, but subsequent
experiments (Fig. 2) indicated that the tracheal fusion cell CRM within B2.7 does not overlap
with C1.7. The D1.4, E3.8, and F3.8 transgenes were not expressed in tracheal fusion cells,
but each was expressed in a Dys+ embryonic cell type, including brain (D1.4), hindgut and
anal pad (E3.8, F3.8) (Fig. 1H–J). Of the 17.2 kb of the dys gene examined, all embryonic
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Dys+ embryonic cell types were observed, except the foregut atrium. In addition, the tracheal
fusion cells, hindgut, and anal pad had at least two distinct CRMs controlling expression.
2.2. Identification of fusion cell-specific dys CRMs
To isolate the dys minimal CRMs from other functional sequences, the B2.7 and C1.7 fragments
were further subdivided, and the fragments tested for fusion cell expression (Fig. 2,3). B2.7
was divided into the G1.7 and H1.0 fragments (Fig. 2A). G1.7 was not expressed in fusion
cells or leading edge (Fig. 2B), whereas H1.0 expression was observed in both cell types (Fig.
2C). Bisection of H1.0 yielded a non-expressing subfragment, I517 (Fig. 2D), and J544, which
drove expression in fusion cells and leading edge (Fig. 2E). When J544 was subdivided into
3 fragments: K152, L156, and M269, none showed expression in fusion cells (Fig. 2F–H),
although M269 had weak leading edge expression (Fig. 2H). These results suggested that fusion
cell and leading edge expression were separable, and that we had disrupted the fusion cell
CRM. Another fragment, N283, which encompassed K152 and L156, was analyzed and had
strong fusion cell and leading edge expression (Fig. 2I). When 3 deletion fragments of N283
were tested, two of them, O191 and P155, drove expression in all fusion cells, but were unable
to drive leading edge expression (Fig. 2J,K). In contrast, no expression was observed from
Q112 (Fig. 2L). Thus, we were able to identify a small fragment of dys, P155, which was
sufficient for fusion cell expression, and independent of leading edge expression. The O191
and P155 fusion cell specific fragments were also each inserted into a ΦC31-based Gal4 vector,
and both transgenic lines were able to drive reporter gene expression specifically in fusion cells
(data not shown), thus providing a fusion cell-specific driver strain for genetic and cell
purification experiments.
All dys fragments with fusion cell expression showed expression in all fusion cells, suggesting
that the regulatory inputs responsible for activating expression in the B2.7 CRM act in all fusion
cells. Analysis of the deletion derivatives of the fusion cell-expressing O191 fragment (K152,
P155, Q112) indicated that there were at least two separable elements required for fusion cell
expression. These reside in O191 at 36–79 and 152–191. Leading edge expression was
observed from 2 adjacent fragments: M269 (weak) and N283 (strong), but the N283 deletions
did not further localize activity. This suggests that multiple elements also contribute to leading
edge expression.
To identify the minimal fusion cell specific enhancer within C1.7, it was dissected into two
fragments: R900 and S832 (Fig. 3A). R900 drove GFP expression in all fusion cells (Fig. 3B),
whereas S832 did not have fusion cell expression. R900 was subdivided into the T523, U400,
and V345 fragments. T523 and V345 drove fusion cell expression (Fig. 3D,F), whereas U400
did not (Fig. 3E). Thus, we identified a second dys fusion cell CRM in a 345 bp stretch of DNA,
and like the B2.7 CRM, the C1.7 CRM is expressed in all fusion cells.
2.3. Bioinformatic identification and in vivo functional analysis of dys CRM sequence motifs
The P155 dys fragment was compared to orthologous sequences in other drosophilids, and
seven conserved regions were selected, deleted individually in P155, and tested for fusion cell
expression by germline transformation. These sequences were: 1 (GATCGG), 2
(TTAAATCAAA), 3 (GCGCG), 4 (TGCCTGAC), 5 (ACTTCCGC), 6 (GACCCAAAAC),
and 7 (TTAATATTCA) (Fig. 4A, Supplementary Fig. 3). The Δ1, Δ2 and Δ6 deletion
transgenes showed fusion cell expression (Fig. 4B,C,G) similar to the unmutated P155
fragment. In contrast, Δ3 and Δ5 resulted in reduced GFP expression, present in only a few
DT and DB fusion cells (Fig. 4D,F). The sequence corresponding to Δ5 (ACTTCCG) resembles
a consensus ETS binding site: (A/G)(C/T)(A/T)TCC(G/T) (Sharrocks et al., 1997). Previous
work showed that the Pointed (Pnt) ETS protein plays a prominent role in tracheal development
as a downstream effector of breathless signaling (Myat et al., 2005;Ohshiro et al., 2002). We
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note that, similar to Δ5, dys expression was reduced in pnt mutant embryos (Fig. 4I,J),
consistent with Pnt directly regulating dys expression. The Δ4 and Δ7 deletions were required
for dys expression, since deletion completely abolished GFP expression in fusion cells (Fig.
4E,H). The sequence corresponding to Δ7 (TTAATATTCA) resembles binding sites for POU-
homeodomain proteins (consensus: TTAAAATTCA) (Okamoto et al., 1990) as determined by
an unbiased search of P155 using TESS (Schug, 2008). The vvl gene encodes a POU-
homeodomain protein gene (Anderson et al., 1995) that can regulate tracheal gene expression
either in conjunction with the Trh bHLH-PAS protein (Zelzer and Shilo, 2000) or
independently of Trh (Boube et al., 2000). If Vvl binds to the Δ7 sequence or some other
sequence in P155, it does so without the partnership of Trh:Tgo, since there is no ACGTG
Trh:Tgo binding site present in P155.
The analysis of dys deletions (Fig. 2) indicated that there were at least two regions of P155
required for fusion cell expression, 1–42 and 117–155. The Δ3 deletion resulted in reduced
fusion cell expression; it overlaps nucleotides 1–42 in P155, and its disruption in Q112 could
contribute to, but not fully explain, the complete loss of expression observed with Q112 (Fig.
2L). The Δ7 deletion, which abolished expression, is present in P155 nucleotides 117–155,
and its role is consistent with the absence of expression observed with K152 (Fig. 2F), which
lacks 117–155.
The Esg zing-finger transcription factor is expressed in all fusion cells, and mutants in esg
results in an absence of dys expression in DB and GB, but not DT (LT dies in esg mutants).
One reported binding site for Esg is (G/A)CAGGTG (Fuse et al., 1994). We did not find
closely–related sequences in dys P155. Consistent with the results on endogenous dys, the
expression of dys P155 and T523 were absent in DB, LT, and GB in esg mutant embryos
(Supplementary Fig. 4A–D). Thus, either Esg does not directly regulate dys, or else we are
unable to identify Esg binding sites bioinformatically.
Sequence analysis of the dys T523 fragment, which drives late fusion cell expression, showed
that it has five Dys:Tgo binding sites (TCGTG) (Supplementary Fig. 5), suggesting the
possibility that T523 is autoregulated by dys. Consistent with this observation, C1.7 expression
was abolished in dys mutant embryos (Fig. 4K) (T523 is derived from C1.7). The 5′-most 345
bp of T523 is well-conserved in the 12 Drosophila species compared, and the 3′-most 178 bp
poorly-conserved (Supplementary Fig. 5). The V345 fragment includes the 5′-most conserved
residues and was able to drive GFP expression in all fusion cells (Fig. 3F). Three of the TCGTG
sites (A–C) are present in V345; TCGTG-C is conserved in all 12 species and TCGTG-A and
TCGTG-B are conserved in 11/12 species. When TCGTG-A and TCGTG-C were deleted
together in V345, only weak GFP expression was observed in fusion cells (Fig. 3G). These
data indicated that the V345 CRM is autoregulated by dys. In contrast, the P155 dys CRM does
not have any TCGTG sequences, and its expression was not altered in dys mutant embryos
(Fig. 4L). Thus, the V345 CRM appears to amplify late dys expression by autoregulation.
2.4. CG13196 fusion cell transcription requires multiple Dys:Tgo binding sites and additional
cis-control elements
The CG13196 gene is expressed specifically in tracheal fusion cells in the embryo (Jiang and
Crews, 2006), and is a direct target of Dys:Tgo (Jiang and Crews, 2007). CG13196 encodes a
member of the zona pellucida (ZP) family of membrane proteins (Jazwinska and Affolter,
2004). Its function is unknown, but overexpression of CG13196 in trachea promotes ectopic
branch fusion, indicating that CG13196 may play a role in membrane adhesion (Jiang and
Crews, 2006). Previously, we identified a 985 bp fragment (A985; Fig. 5A) in the CG13196
5′-flanking region that drove fusion cell expression (Jiang and Crews, 2007). This fragment
contains 3 TCGTG (Dys:Tgo) sequences. Mutation of all 3 sites resulted in loss of fusion cell
expression, indicating that Dys:Tgo directly regulates CG13196. However, this experiment did
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not address whether all 3 TCGTG sequences were required for fusion cell expression, and if
not, which ones are important. The A985 fragment was first subdivided into two fragments:
B490 that contains TCGTG-A, and C350 that contain TCGTG-B and TCGTG-C (Fig. 5A).
These fragments were tested for fusion cell expression in vivo. B490 was unable to drive
GFP expression in fusion cells (Fig 5B), whereas the C350 transgene drove GFP expression
in all fusion cells (Fig 5C). This indicated that TCGTG-A is not required for CG13196 fusion
cell expression, nor is it able to drive fusion cell expression by itself. D92 is a 92 bp derivative
of C350 that contains both TCGTG-B and TCGTG-C. It was able to promote fusion cell
expression (Fig 5D), and its expression relatively late in development (Supplementary Fig.
2P–T) mimicked endogenous CG13196. Both TCGTG motifs were deleted individually in the
context of D92 and tested for fusion cell activity. Deletion of either TCGTG-B or TCGTG-C
resulted in an absence of fusion cell expression (Fig. 5E–M). To rule out the possibility that
the deletions affected the arrangement along the DNA of nearby cis-control elements other
than TCGTG motif, the D92 TCGTG motifs were individually mutated to CAATG. Mutation
of either TCGTG-B or TCGTG-C also resulted in the absence of fusion cell expression (Fig.
5N–S). These results indicated that both Dys:Tgo binding sites are required for fusion cell
expression.
Bioinformatic analysis of the CG13196 D92 fragment revealed strong conservation among the
12 Drosophila species. There were 4 major blocks of conservation: two corresponding to the
two Dys:Tgo TCGTG sequences, and two to a repeated 11 bp motif (CCATGGAAAGT and
CCATTAAAAGT) referred to as Motif 1 (Supplementary Fig. 6). When both instances of
Motif 1 were deleted in D92, no fusion cell expression was observed (Fig. 5T–V). Thus, these
sequences may be sites for a fusion cell coactivator that functions in conjunction with Dys:Tgo.
However, Motif 1 sequences by themselves are unable to drive fusion cell expression, since
when the TCGTG sequences were mutated in D92, all fusion cell expression was lost, despite
the presence of the Motif 1 sequences. One of the Dys:Tgo binding sites (TCGTG-B) was
immediately preceded by AAG. It was also noticed that AAG precedes two of the 5 TCGTG
sequences in dys T523 (Supplementary Fig. 5) and both TCGTGs important for CG15252
expression (see below; Supplementary Fig. 7), suggesting this motif may be important for
fusion cell expression. However, deletion of the CG13196 TCGTG-C AAG motif did not affect
GFP expression in fusion cells (Fig 5W–Y).
2.5. The DT-specific fusion cell-expressed gene CG15252 is directly regulated by Dys:Tgo
The CG15252 gene is expressed only in DT fusion cells, and its expression requires dys
function (Jiang and Crews, 2006). The function of CG15252 is unknown, but it does share
sequence homology with the bacterial FtsI protein that is a transpeptidase involved in cell wall
peptidoglycan synthesis and cell division (Errington et al., 2003). The CG15252 gene has 9.9
kb of 5′-flanking sequence and 4 relatively small introns. We hypothesized that Dys:Tgo
directly regulates CG15252 expression in DT, and selected an 818 bp fragment that contains
4 TCGTG sequences to analyze in vivo for fusion cell expression (Fig. 6A). This fragment is
6.8 kb upstream of the 5′ end of the longest cDNA clone. The A818 fragment drove GFP
expression only in DT fusion cells (Fig 6B), similar to endogenous CG15252. To test which
TCGTG sites are required for CG15252 fusion cell expression, fragment B270, containing the
TCGTG-A and TCGTG-B sites, and fragment C100, containing the TCGTG-C and TCGTG-
D sites, were analyzed. B270 was unable to drive GFP expression in DT fusion cells (Fig 6C),
whereas the C100 transgenic line had expression in DT fusion cells (Fig 6D), and was expressed
late in development similar to CG15252 (Supplementary Fig. 2U,V). Individually deleting or
mutating both TCGTG-C and TCGTG-D resulted in a loss of fusion cell GFP expression (Fig.
6E–S). Thus, similar to CG13196, tracheal fusion cell expression requires two clustered
Dys:Tgo binding sites, both of which are essential for expression.
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Bioinformatic analysis of the C100 sequence revealed strong conservation among 4 species
closely related to D. melanogaster (Supplementary Fig. 7). However, significant sequence
similarity was not found in 7 other sequenced Drosophila species. Among the 5 related species,
the C100 sequence had two instances of a conserved 6 bp motif, named Motif 2. Deletion of
both Motif 2 sequences in C100 had no effect on fusion cell expression (Fig. 6T–V). Both of
the conserved TCGTG sequences in C100 are preceded by a conserved AAG motif. Deletion
of both AAG sequences together had no effect on C100 fusion cell GFP expression (Fig 6W–
Y).
2.6. CG13196 has coactivator sequences that promote expression in DB, LT, and GB
Despite the similarity in the requirement of two adjacent Dys:Tgo binding sites for fusion cell
expression, CG13196 is expressed in all fusion cells, whereas CG15252 is only expressed in
DT. Both Dys and Tgo are present in all fusion cells. There are four general models that could
explain the expression differences: (1) Dys:Tgo is able to activate transcription through the
presence of one or more binding sites in all fusion cells, and CG15152 has sequences that
repress expression in DB, LT, and GB; (2) Dys:Tgo is only able to activate expression in DT
by itself, but CG13196 has sequences for a coactivator that allows expression in DB, LT, and
GB; (3) Dys:Tgo can activate transcription in fusion cells only in cooperation with additional
coactivators, including one functioning in all fusion cells (CG13196; dys autoregulation), and
another in only DT (CG15252); and (4) Differential activation depending on the spacing/
orientation of Dys:Tgo sequences.
An initial test of these hypotheses was carried-out by fusing fragments containing fusion cell
CRMs of CG13196 and CG15252 to each other, and testing their effects in vivo. To test the
hypothesis that coactivators are required to turn on CG13196 in fusion cells other than DT, a
chimeric enhancer containing CG13196 C350 with deleted TCGTG sites was fused with
CG15252 C100 with both TCGTG sites intact (Fig. 7A). If the hypothesis that CG13196 has
coactivator sequences for DB, LT, and GB (and possibly, DT) expression is correct, they may
work in conjunction with the CG15252 TCGTG sequences to activate expression in all fusion
cells. This is what was observed (Fig. 7C). The complementary experiment involved fusing
CG15252 C100 with both TCGTG binding sites deleted to CG13196 C350 that had both
TCGTG sequences intact (Fig. 7B). If CG15252 has corepressor sequences that restrict its
expression to DT, then these repressive sequences could act in combination with the
CG13196 TCGTG sequences to limit expression to DT. This was not observed; the chimeric
transgene was expressed in all fusion cells (Fig. 7D). Thus, these experiments provide evidence
for sequences in CG13196 that work in conjunction with Dys:Tgo binding sites to allow
expression in all fusion cells. In contrast, we did not find evidence for sequences in
CG15252 that restrict expression to DT. However, this may still be the case, since it is possible
that they cannot function in the context of CG13196 C350.
3. Discussion
Tracheal fusion cells are a complex cell type that direct tracheal cell migration, recognition,
adhesion, and cellular remodeling upon fusion. It is expected that these morphogenetic events
will be accompanied by sophisticated regulatory pathways. The major goal of this work is to
mechanistically explore the transcriptional circuitry that governs tracheal fusion cell function.
We selected 3 genes to investigate, since each has a unique mode of fusion cell expression,
while also sharing common features. Both dys and CG13196 are expressed in all fusion cells,
but dys precedes CG13196 in developmental expression. CG13196 and CG15252 are target
genes of dys, but CG15252 is only expressed in DT fusion cells. Employing transgenic reporter
analysis of fragments of 5′-flanking and intronic sequences, we were able to identify fusion
cell CRMs for each gene. After reducing the size of each fragment by deletional analysis,
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phylogenetic-assisted bioinformatics was employed to identify DNA sequences that are
potential binding sites for transcription factors. Mutational analysis was carried-out and
demonstrated the functionality of several motifs. An additional goal, which was successful,
was to generate fusion cell-specific Gal4 lines that could be used for fusion cell purification
or molecular analyses.
3.1. The dys gene contains multiple fusion cell CRMs
The dys gene is expressed in fusion cells from stages 12–17, and we identified two distinct
CRMs that drive dys fusion cell expression. Additional embryonic pattern elements associated
with dys expression were identified, including leading edge cells, hindgut, anal pad, and brain.
The P155 fragment drove reporter gene expression from stages 12–17, and likely represents
the CRM governing initial dys expression. The T523 CRM contains a dys autoregulatory CRM
expressed from stages 14–17, since its expression was absent in dys mutant embryos and
strongly reduced when two Dys:Tgo binding sites were deleted. Given the potential stability
of GFP, it is unclear whether expression of P155 is maintained during later stages, and overlaps
with the T523 CRM. However, previous work indicated that null dys mutant embryos possessed
substantial dys RNA in late stage embryos (Jiang and Crews, 2003). This suggests that dys-
independent transcription, likely derived from the P155 CRM, is still able to contribute
detectable levels of dys RNA in a dys mutant. Thus, the dys autoregulatory CRM likely
amplifies dys transcription (Crews and Pearson, 2009), but is not solely responsible for late
embryonic expression.
Little is known regarding how dys expression is initiated in fusion cells. One potential regulator
is the Esg zinc finger protein. Esg is present in all fusion cells, and precedes initial dys
expression. Analysis of esg mutant embryos indicated that esg was required for dys expression
in DB and GB, but not DT (Jiang and Crews, 2003). Since LT undergoes apoptosis in esg
mutants (Samakovlis et al., 1996), it is unclear whether LT dys expression requires esg function.
These results are consistent with Esg directly regulating dys in some fusion cells, but not others.
By narrowing the limits of the dys stage 12–17 fusion cell CRM to 155 bp (P155), bioinformatic
analyses were carried-out to potentially identify transcription factor binding sites, followed by
mutagenesis and assaying function in vivo.
Seven conserved sequences from 5 to 10 bp in length were deleted in P155. The results of the
deletion experiments indicated that deletions 1, 2, and 6 had no effect on expression; deletions
3 and 5 showed a reduction in fusion cell expression; and deletions 4 and 7 were required for
all fusion cell expression. These results were consistent with the deletional analysis of the
dys B2.7 fragment (Fig. 2) that indicated at least two separate regions were required for dys
expression. One contained sequences 1–3 and the other sequence 7, and individual deletions
Δ3 and Δ7 had expression defects. The consensus Esg binding site is: (G/A)CAGGTG, and no
sequence strongly resembled this motif in P155. In addition, no deletion tested resulted in
altered P155 GFP expression resembling the esg mutant phenotype (loss of expression in DB
and GB, but no effect on DT). Instead, all mutants affected all 4 fusion cell types. Thus Esg
either does not directly regulate dys transcription, or regulates transcription via binding to sites
in P155 not clearly related to the known binding site sequence and not overlapping with Δs1–
7. Future work employing in vitro binding studies with Esg protein or use of chromatin
immunoprecipitation (ChIP) techniques from embryonic cells would help resolve this issue.
Two of the deleted sites required for high levels of expression are related to known transcription
factor binding sites: the Δ5 site corresponds to an ETS protein binding site, and Δ7 to a POU
homeodomain binding site. One ETS family protein, Pointed, is the transcriptional effector of
the branchless/breathless signaling pathway required for tracheal branching (Myat et al.,
2005; Ohshiro et al., 2002; Sutherland et al., 1996). Embryos mutant for pnt show a strong
reduction of dys tracheal expression. While this does not prove that breathless signaling and
Jiang et al. Page 8













Pointed directly regulate the sequence affected by the Δ5 deletion, the effects of both deleting
the ETS site and pnt mutants support that possibility. It is possible that high levels of dys
expression in fusion cells require continual signaling from branchless. One prominent tracheal-
expressed POU homeodomain protein is Vvl. Mutants in vvl result in an early failure of tracheal
branching and general absence of differentiation (Anderson et al., 1995; Llimargas and
Casanova, 1997). One study proposed that Vvl is a coactivator of tracheal transcription along
with the Trh:Tgo heterodimeric tracheal master regulator (Zelzer and Shilo, 2000). While the
Δ7 sequence resembles a POU homeodomain sequence, this site does not strongly resemble
known Vvl binding sites. Similarly, there are no Trh:Tgo binding sites (ACGTG) within P155,
so positive evidence of dys direct regulation by Trh and Vvl is lacking. Thus, if D7 binds Vvl,
then it may function independently of Trh, as was observed for regulation of thick veins, a
tracheal-expressed genetic target of vvl (Boube et al., 2000; Llimargas and Casanova, 1997).
In summary, these data suggest multiple distinct binding sites (at least 4) contribute to dys
expression, and one of the regulators may be Pnt.
One model for dys expression is that separate CRMs drive expression in fusion cells
corresponding to each branch. In the most extreme case, there would be 4 CRMs, each
controlling DB, DT, LT, and GB fusion cell expression. Alternatively, there may be a single
CRM that responds to the same transcription factors present in each fusion cell type. None of
the deletions of dys B2.7 or the P155 deletions revealed evidence of branch-specific CRMs –
all fusion cells were affected. In addition, none of the deletions resulted in temporal differences
of expression: in each case expression was affected similarly from stages 12–17. Thus, while
there may exist subtle differences regarding how different fusion cell types are regulated by
dys B2.7, at a gross level the current data suggest that the same CRM responds to the same or
similar transcription factors in each fusion cell type.
3.2. Analysis of CG13196 fusion cell expression reveals the existence of a Dys:Tgo
coactivator
The CG13196 gene is expressed in all tracheal fusion cells, and is directly regulated by
Dys:Tgo. The A985 bp fragment of CG13196 is sufficient for expression in fusion cells, and
contains 3 TCGTG Dys:Tgo binding sites. Previously, it was demonstrated that mutation of
all 3 sites together resulted in loss of fusion cell expression (Jiang and Crews, 2007). In this
paper, we individually deleted each site, and showed that TCGTG-A is not required for fusion
cell expression, but both TCGTG-B and TCGTG-C are. Furthermore, bioinformatic analysis
revealed the presence of two related sequence motifs. When these sequences (referred to as
Motif 1) were deleted together, there was a complete absence of expression in all fusion cells.
This suggests that an additional transcription factor, possibly binding to the Motif 1 sequences,
acts as a transcriptional coactivator with Dys:Tgo. Further evidence for an additional
coactivator in the CG13196 CRM came from analysis of a hybrid CRM in which the
CG15252 CRM that is expressed in only DT fusion cells was fused to CG13196 C350 with
both TCGTG sequences deleted. This chimeric CRM was expressed in all fusion cells,
indicating that sequences in CG13196 C350 (unknown, but possibly Motif 1) in addition to
the Dys:Tgo binding sites are important for driving expression in all fusion cells. Most likely,
the CG13196 ΔTCGTG fusion cell CRM requires the CG15252 TCGTG sequences for proper
fusion cell expression.
3.3. CG15252 is a direct target of Dys:Tgo
The CG15252 gene is expressed in only the DT fusion cells, and genetically requires dys. The
A818 fragment has 4 TCGTG sequences. Deletion of TCGTG-A and TCGTG-B had no effect
on expression. However, deletion of TCGTG-C and TCGTG-D resulted in an absence of fusion
cell expression, indicating that CG15252 is a direct target of Dys:Tgo. In both in vitro DNA
binding and S2 cell transient transfection experiments, Dys:Tgo was able to bind to and activate
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transcription from ACGTG, GCGTG, and TCGTG sequences (Jiang and Crews, 2007).
However, analysis of CG13196 indicated that only the TCGTG motif was required for
expression in vivo (Jiang and Crews, 2007). The CG15252 C100 fragment has two TCGTG
sequences shown to be important for fusion cell transcription, and no ACGTG or GCGTG
sequences are present. Similarly, the T523 putative dys autoregulatory element has 5 TCGTG
motifs but no ACGTG or GCGTG motifs. Thus, in vivo evidence to date indicates that Dys:Tgo
activates transcription via TCGTG, and not other NCGTG sequences.
It was noted that both CG15252 TCGTG sequences were preceded by AAG, as was one of the
two CG13196 TCGTG sequences, and two of five dys T523 TCGTGs. One hypothesis tested
was that this variant AAGTCGTG motif may have special significance regarding fusion cell
expression. However, deletion of the AAG sequences in both CG13196 and CG15252 had no
effect on expression. Thus, the core TCGTG sequence is critical, but the precise sequence of
flanking residues less so. This is similar to results observed with other bHLH-PAS proteins
(Single-minded, Trh, Hypoxia Inducible Factor-1α/Sima, Aryl hydrocarbon receptor/
Spineless) that form heterodimers with Tgo/Arnt, in which a core NCGTG sequence is invariant
but flanking residues much less conserved (Semenza et al., 1996; Swanson et al., 1995;
Wharton et al., 1994). We identified a repeated motif (Motif 2 in C100) in CG15252, but
deletion of both sites together had no effect on expression.
One of the major issues is why CG15252 is expressed in only DT. One model is that Dys:Tgo
binding sites are sufficient for only DT expression, and additional expression in all fusion cells
requires binding sites for another activator: thus CG13196 would possess these additional
coactivator binding sites and CG15252 would not. This seems unlikely since multimerization
of only TCGTGs results in expression in all fusion cells (Jiang and Crews, 2007). While
different arrangements of TCGTG sequences between CG13196 and CG15252 are a
possibility, both genes have a relatively similar arrangement: two required TCGTG sequences
within 40 bp of each other. Another possibility is that the CG15252 CRM contains a repressor
of DB, LT, and GB, so that in combination with multiple Dys:Tgo binding sites, restriction to
DT occurs. There are no data that contradict this model, but no data to support it. The Motif 2
sequences are unlikely to be corepressor binding sites, since their deletion had no effect on
expression, but other, untested sequences in CG15252 may carry-out this role. When the
CG15252 C100 fragment with deleted TCGTG sequences was fused to CG13196 C350, the
hybrid fragment was able to drive expression in all fusion cells. This indicated that if a repressor
sequence exists on C100 it is unable to repress transcription of the CG13196 fragment. Another
model is that Dys:Tgo is able to activate transcription in fusion cells only in the presence of
specific coactivators. In this case, CG13196 would include an activator present in all fusion
cells, which is consistent with the Motif 1 sequences. CG15252 would require a coactivator
present or functional in only DT cells. If so, we have not yet identified sites corresponding to
this coactivator. We note that the knirps, knirps-like (also knirps-related), and spalt genes play
important roles in defining tracheal branch-specific gene regulation (Chen et al., 1998; Franch-
Marro and Casanova, 2002; Kuhnlein and Schuh, 1996; Ohshiro et al., 2002), and it is possible
that these genes either indirectly or directly play a role in CG15252 DT-specific expression.
3.4. Search for a fusion cell regulatory code
One of the major goals of the research described in this paper is to begin to identify the CRMs
and corresponding transcription factors that govern fusion cell gene regulation. Since fusion
cells undergo a variety of developmental changes, an important aspect of mechanistically
understanding how these changes occur concerns understanding transcriptional control. The
dys gene plays an important role in controlling fusion cell development. One of the key results
emerging from the analysis of the dys gene is that its expression requires multiple inputs. In
particular, the finding of an essential ETS binding site provides unexpected evidence that direct
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input from the branchless/breathless/pointed signaling pathway may be required for dys
expression. We have identified three direct targets of dys action, including dys itself as an
autoregulatory target, CG13196, and CG15252. Each of these genes possesses multiple binding
sites for Dys:Tgo. However, searching the genome for two TCGTG sites within 40 bp (the
arrangement for CG13196 and CG15252) yields 6,673 hits (Markstein et al., 2002), which is
unlikely to be helpful in identifying fusion-expressed genes. We have also provided evidence
for an additional coactivator required for expression of CG13196 in all fusion cells, possibly
corresponding to Motif 1. However, we currently do not know the transcription factor
corresponding to this coactivator, or whether similar sequences are present in other target genes
of dys expressed in all fusion cells, including the dys autoregulatory element. Another important
issue, unresolved in this paper, concerns how branch-specific fusion cell transcription is
regulated. The answers to this issue and others will require molecular, genetic, and biochemical
analyses of additional fusion cell-expressed genes.
4. Materials and methods
4.1. Mutant Drosophila strains
The null mutant strains of Drosophila utilized were: dys1 (Jiang and Crews, 2006), esgG66
(Samakovlis et al., 1996), and pntΔ88 (Scholz et al., 1993).
4.2. Construction of the pMintGate ΦC31 transformation vector
The Drosophila Gateway-compatible ΦC31 transformation vector, pBPGw (Pfeiffer et al.,
2008), was digested with BglII and SpeI to excise the Gal4 reporter gene. pH-Stinger-GFP
(Barolo et al., 2000) was digested with BglII and SpeI, and a fragment containing an Hsp70
minimal promoter, GFP coding sequence with nuclear localization sequence, 3′-UTR, and poly
(A) addition site was ligated into pBPGw. This vector, named pMintGate, is ΦC31-compatible
with a nuclear-GFP reporter and Gateway sites for cloning fragments adjacent to the Hsp70
promoter (Supplementary Fig. 1).
4.3. Generation of transgenic strains
dys transgenic enhancer tester strains—DNA fragments containing sequences from
the dys gene 5′-flanking region and introns 1 and 2 of the dys gene were PCR-amplified, and
initially cloned into pCR8/GW/TOPO (Invitrogen) or pGEM-T Easy (Promega). The primer
pairs employed for PCR are shown in Supplementary Table 1. The inserts in pCR8 were then
cloned into pMintGate using Gateway LR Clonase II plus (Invitrogen). The inserts in pGEM-
T Easy were removed by restriction digestion with KpnI and BamHI, and then ligated into the
KpnI and BamHI sites of pH-Stinger. Each pMintGate construct was microinjected into
Drosophila embryos that express germline-localized φC31 integrase and contain the φC31
genomic destination site attP2 (68A1-B2) (Groth et al., 2004). The pH-Stinger constructs were
introduced into germline DNA by microinjection using standard techniques. Three independent
lines of each transgene were analyzed for embryonic GFP expression.
dys deletion strains—The dys P155 fragment, which can drive tracheal fusion cell
expression, was used to delete conserved sequences for testing functional significance in vivo.
The following individual deletions were generated using QuickChange II XL site-mutagenesis
kit (Stratagene): Δ1 (GATCGG); Δ2 (TTAAATCAAA); Δ3 (GCGCG); Δ4 (TGCCTGAC);
Δ5 (ACTTCCGC); Δ6 (GACCCAAAAC); and Δ7 (TTAATATTCA). The dys V345 TCGTG-
A and TCGTG-C sequences were deleted together. The altered fragments were cloned into
pMintGate for introduction at attP2 (68A1-B2).
CG13196 transgenic strains—DNA fragments containing 5′-flanking sequences of
CG13196 were PCR-amplified using the primers shown in Supplementary Table 1.
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CG13196 D92, which drives expression in all fusion cells, contains two TCGTG sites, TCGTG-
B and TCGTG-C, two instances of Motif 1 (CCATGGAAAGT and CCATTAAAAGT), and
one AAG site adjacent to TCGTG-C. Four mutant constructs were generated in which each
TCGTG site was individually deleted or individually mutated to CAATG. The AAG site was
individually deleted, and the two Motif 1 sites were deleted together. Mutated fragments were
cloned into pMintGate and integrated at attP2 (68A1-B2).
CG15252 transgenic strains—The DNA fragments containing 5′-flanking sequences of
CG15252 were PCR-amplified using the primers indicated in Supplementary Table 1. The
CG15252 C100 fragment, which drives DT expression, was used to test the function of motifs.
CG15252 C100 has two TCGTG sequences, TCGTG-C and TCGTG-D, and each was
individually deleted and individually mutated to CAATG. The two Motif 2 sites present in
C100 were deleted together, and the two AAG sites adjacent to both TCGTGs were deleted
together.
Chimeric CG13196-CG15252 transgenic strains. CG13196-C350ΔBC:CG15252-
C100—CG15252 C100 was cloned into pCR8/GW/TOPO using TA cloning. CG13196 C350
with deleted TCGTG sites was PCR-amplified using:
AAGCTTTGGCAAGTGATTTGTGGGACA and
AAGCTTGATTGGGCCGCAAGTGATATG (HindIII sites are underlined), and this
fragment was cloned into the Hind III site of pCR8/GW/TOPO-CG15252-C100 to yield
CG13196-C350ΔBC:CG15252-C100. CG15252-C100ΔCD:CG13196-C350. This construct
was generated similar to CG13196-C350ΔBC:CG15252-C100, except that C350 was first
cloned into pCR8/GW/TOPO and C100 with deleted TCGTGs added.
4.4 Immunostaining of embryos
Whole-mount embryos were immunostained using standard techniques (Patel et al., 1987). The
following antibodies were used for immunostaining: rat anti-Dys (1:200), rabbit anti-GFP
(1:1000; Abcam), Alexa Fluor 488-labeled anti-rabbit IgG (1:200; Invitrogen), and Cy3-
labeled anti-rat IgG (1:200; PerkinElmer).
4.5 Bioinformatic analysis of regulatory regions
For each minimal fusion cell-expressed fragment (dys P155, dys T523, CG13196 D92,
CG15252 C100), orthologous sequences from the 12 sequenced drosophilids were retrieved
using the UCSC genome browser, and aligned by T-Coffee (Notredame et al., 2000). Local
sub-alignments were hand-corrected using Lalign (Huang and Miller, 1991) to identify short
regions of homology. Statistically over-represented motifs were identified within and between
co-expressed fusion cell CRMs using PhyloGibbs (Siddharthan et al., 2005; Siddharthan,
2008). WinDotter (Sonnhammer and Durbin, 1995) was used to search for repeated motifs and
palindromes within each enhancer sequence. Identified motifs were compared to consensus
binding sites for known fusion cell-specific transcription factors and to matrices in the JASPAR
and TRANSFAC databases using the TESS motif search program (Schug, 2008). GenePalette
(Rebeiz and Posakony, 2004) was used to annotate genomic DNA sequences and to visualize
putative transcription factor binding site locations within each fragment. FlyEnhancer
(Markstein et al., 2002) was used to search for clusters of Dys:Tgo consensus sites in the D.
melanogaster genome.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Jiang et al. Page 12














This project was funded by grants from the National Science Foundation (Developmental Mechanisms), NICHD, and
the National Center for Research Resources (National Institutes of Health) to STC. The UNC Developmental Biology
NIH training grant provided support to JCP.
References
Anderson MG, Perkins GL, Chittick P, Shrigley RJ, Johnson WA. drifter, a Drosophila POU-domain
transcription factor, is required for correct differentiation and migration of tracheal cells and midline
glia. Genes Dev 1995;9:123–137. [PubMed: 7828848]
Barolo S, Carver LA, Posakony JW. GFP and beta-galactosidase transformation vectors for promoter/
enhancer analysis in Drosophila. Biotechniques 2000;29:726–732. [PubMed: 11056799]
Boube M, Llimargas M, Casanova J. Cross-regulatory interactions among tracheal genes support a co-
operative model for the induction of tracheal fates in the Drosophila embryo. Mech Dev 2000;91:271–
278. [PubMed: 10704851]
Chen CK, Kuhnlein RP, Eulenberg KG, Vincent S, Affolter M, Schuh R. The transcription factors
KNIRPS and KNIRPS RELATED control cell migration and branch morphogenesis during Drosophila
tracheal development. Development 1998;125:4959–68. [PubMed: 9811580]
Crews ST, Pearson JC. Transcriptional autoregulation in development. Curr Biol 2009;19:R241–6.
[PubMed: 19321138]
Errington J, Daniel RA, Scheffers DJ. Cytokinesis in bacteria. Microbiol Mol Biol Rev 2003;67:52–65.
[PubMed: 12626683]
Franch-Marro X, Casanova J. spalt-induced specification of distinct dorsal and ventral domains is
required for Drosophila tracheal patterning. Dev Biol 2002;250:374–82. [PubMed: 12376110]
Fuse N, Hirose S, Hayashi S. Diploidy of Drosophila imaginal cells is maintained by a transcriptional
repressor encoded by escargot. Genes Dev 1994;8:2270–2281. [PubMed: 7958894]
Groth AC, Fish M, Nusse R, Calos MP. Construction of transgenic Drosophila by using the site-specific
integrase from phage phiC31. Genetics 2004;166:1775–1782. [PubMed: 15126397]
Huang X, Miller W. A time-efficient, linear-space local similarity algorithm. Adv Appl Math
1991;12:337–357.
Isaac DD, Andrew DJ. Tubulogenesis in Drosophila: a requirement for the trachealess gene product.
Genes Dev 1996;10:103–117. [PubMed: 8557189]
Jazwinska A, Affolter M. A family of genes encoding zona pellucida (ZP) domain proteins is expressed
in various epithelial tissues during Drosophila embryogenesis. Gene Expr Patterns 2004;4:413–421.
[PubMed: 15183308]
Jiang L, Crews ST. The Drosophila dysfusion basic helix-loop-helix (bHLH)-PAS gene controls tracheal
fusion and levels of the trachealess bHLH-PAS protein. Mol Cell Biol 2003;23:5625–5637.
[PubMed: 12897136]
Jiang L, Crews ST. Dysfusion transcriptional control of Drosophila tracheal migration, adhesion, and
fusion. Mol Cell Biol 2006;26:6547–6556. [PubMed: 16914738]
Jiang L, Crews ST. Transcriptional specificity of Drosophila dysfusion and the control of tracheal fusion
cell gene expression. J Biol Chem 2007;282:28659–28668. [PubMed: 17652079]
Kuhnlein RP, Schuh R. Dual function of the region-specific homeotic gene spalt during Drosophila
tracheal system development. Development 1996;122:2215–23. [PubMed: 8681802]
Lavista-Llanos S, Centanin L, Irisarri M, Russo DM, Gleadle JM, Bocca SN, Muzzopappa M, Ratcliffe
PJ, Wappner P. Control of the hypoxic response in Drosophila melanogaster by the basic helix-loop-
helix PAS protein similar. Mol Cell Biol 2002;22:6842–53. [PubMed: 12215541]
Lee S, Kolodziej PA. The plakin Short Stop and the RhoA GTPase are required for E-cadherin-dependent
apical surface remodeling during tracheal tube fusion. Development 2002;129:1509–20. [PubMed:
11880359]
Llimargas M, Casanova J. ventral veinless, a POU domain transcription factor, regulates different
transduction pathways required for tracheal branching in Drosophila. Development 1997;124:3273–
3281. [PubMed: 9310322]
Jiang et al. Page 13













Manning, G.; Krasnow, MA. Development of the Drosophila Tracheal System. In: Bate, M.; Martinez
Arias, A., editors. The Development of Drosophila Melanogaster. Cold Spring Harbor, N. Y: Cold
Spring Harbor Laboratory Press; 1993. p. 609-685.
Markstein M, Markstein P, Markstein V, Levine MS. Genome-wide analysis of clustered Dorsal binding
sites identifies putative target genes in the Drosophila embryo. Proc Natl Acad Sci U S A
2002;99:763–768. [PubMed: 11752406]
Mortimer NT, Moberg KH. The Drosophila F-box protein Archipelago controls levels of the Trachealess
transcription factor in the embryonic tracheal system. Dev Biol 2007;312:560–571. [PubMed:
17976568]
Myat MM, Lightfoot H, Wang P, Andrew DJ. A molecular link between FGF and Dpp signaling in
branch-specific migration of the Drosophila trachea. Dev Biol 2005;281:38–52. [PubMed:
15848387]
Nambu JR, Chen W, Hu S, Crews ST. The Drosophila melanogaster similar bHLH-PAS gene encodes
a protein related to human Hypoxia-inducible factor 1αDrosophila Single-minded. Gene
1996;172:249–254. [PubMed: 8682312]
Notredame C, Higgins DG, Heringa J. T-Coffee: A novel method for fast and accurate multiple sequence
alignment. J Mol Biol 2000;302:205–217. [PubMed: 10964570]
Ohshiro T, Emori Y, Saigo K. Ligand-dependent activation of breathless FGF receptor gene in Drosophila
developing trachea. Mech Dev 2002;114:3. [PubMed: 12175485]
Okamoto K, Okazawa H, Okuda A, Sakai M, Muramatsu M, Hamada H. A novel octamer binding
transcription factor is differentially expressed in mouse embryonic cells. Cell 1990;60:461–472.
[PubMed: 1967980]
Ooe N, Saito K, Mikami N, Nakatuka I, Kaneko H. Identification of a novel basic helix-loop-helix-PAS
factor, NXF, reveals a Sim2 competitive, positive regulatory role in dendritic-cytoskeleton modulator
drebrin gene expression. Mol Cell Biol 2004;24:608–616. [PubMed: 14701734]
Ooe N, Saito K, Oeda K, Nakatuka I, Kaneko H. Characterization of Drosophila and Caenorhabditis
elegans NXF-like-factors, putative homologs of mammalian NXF. Gene 2007;400:122–130.
[PubMed: 17628356]
Patel NH, Snow PM, Goodman CS. Characterization and cloning of fasciclin III: a glycoprotein expressed
on a subset of neurons and axon pathways in Drosophila. Cell 1987;48:975–988. [PubMed: 3548998]
Pfeiffer BD, Jenett A, Hammonds AS, Ngo TT, Misra S, Murphy C, Scully A, Carlson JW, Wan KH,
Laverty TR, Mungall C, Svirskas R, Kadonaga JT, Doe CQ, Eisen MB, Celniker SE, Rubin GM.
Tools for neuroanatomy and neurogenetics in Drosophila. Proc Natl Acad Sci U S A 2008;105:9715–
9720. [PubMed: 18621688]
Rebeiz M, Posakony JW. GenePalette: a universal software tool for genome sequence visualization and
analysis. Dev Biol 2004;271:431–438. [PubMed: 15223345]
Samakovlis C, Manning G, Steneberg P, Hacohen N, Cantera R, Krasnow MA. Genetic control of
epithelial tube fusion during Drosophila tracheal development. Development 1996;122:3531–6.
[PubMed: 8951068]
Scholz H, Deatrick J, Klaes A, Klambt C. Genetic dissection of pointed, a Drosophila gene encoding two
ETS-related proteins. Genetics 1993;135:455–468. [PubMed: 8244007]
Schug J. Using TESS to predict transcription factor binding sites in DNA sequence. Curr Protoc
Bioinformatics 2008;Chapter 2(Unit 2.6)
Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A. Hypoxia response
elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential
binding sites for hypoxia-inducible factor 1. J Biol Chem 1996;271:32529–32537. [PubMed:
8955077]
Sharrocks AD, Brown AL, Ling Y, Yates PR. The ETS-domain transcription factor family. Int J Biochem
Cell Biol 1997;29:1371–1387. [PubMed: 9570133]
Siddharthan R. PhyloGibbs-MP: module prediction and discriminative motif-finding by Gibbs sampling.
PLoS Comput Biol 2008;4:e1000156.1–e1000156.15. [PubMed: 18769735]
Siddharthan R, Siggia ED, van Nimwegen E. PhyloGibbs: a Gibbs sampling motif finder that incorporates
phylogeny. PLoS Comput Biol 2005;1:e67.0534–e67.0556. [PubMed: 16477324]
Jiang et al. Page 14













Sonnenfeld M, Ward M, Nystrom G, Mosher J, Stahl S, Crews S. The Drosophila tango gene encodes a
bHLH-PAS protein that is orthologous to mammalian Arnt and controls CNS midline and tracheal
development. Development 1997;124:4583–4594. [PubMed: 9409675]
Sonnhammer EL, Durbin R. A dot-matrix program with dynamic threshold control suited for genomic
DNA and protein sequence analysis. Gene 1995;167:GC1–10. [PubMed: 8566757]
Sutherland D, Samakovlis C, Krasnow MA. branchless encodes a Drosophila FGF homolog that controls
tracheal cell migration and the pattern of branching. Cell 1996;87:1091–1101. [PubMed: 8978613]
Swanson HI, Chan WK, Bradfield CA. DNA binding specificities and pairing rules of the Ah receptor,
ARNT, and SIM proteins. J Biol Chem 1995;270:26292–26302. [PubMed: 7592839]
Tanaka-Matakatsu M, Uemura T, Oda H, Takeichi M, Hayashi S. Cadherin-mediated cell adhesion and
cell motility in Drosophila trachea regulated by the transcription factor Escargot. Development
1996;122:3697–705. [PubMed: 9012491]
Wharton JKA, Franks RG, Kasai Y, Crews ST. Control of CNS midline transcription by asymmetric E-
box elements: similarity to xenobiotic responsive regulation. Development 1994;120:3563–3569.
[PubMed: 7821222]
Wilk R, Weizman I, Glazer L, Shilo B. trachealess encodes a bHLH-PAS protein and is a master regulator
gene in the Drosophila tracheal system. Genes Dev 1996;10:93–102. [PubMed: 8557198]
Zelzer E, Shilo B. Interaction between the bHLH-PAS protein Trachealess and the POU-domain protein
Drifter, specifies tracheal cell fates. Mech Dev 2000;19:163–173. [PubMed: 10704841]
Jiang et al. Page 15














Transgenic analysis of the dys regulatory region. (A) Schematic illustrating 32 kb of the
genomic region encompassing the dys gene. The 10 dys exons are indicated as blocks: coding
sequences are filled and untranslated regions unfilled. The direction of transcription is indicated
by the arrow. Fragments analyzed as reporter transgenes are labeled A–F with the size of the
fragment in kb included. Fragments colored green indicate they drove expression in fusion
cells. Stage 15 or 16 embryos from transgenic reporter-GFP strains were stained with anti-GFP
(green) and anti-Dys (magenta) antibodies. All images depict sagittal views and anterior is to
the left. (B) A3.8 drove GFP expression in subsets of ectodermal cells (arrow: here and
throughout) that did not overlap with Dys+ cells. These cells were commonly observed with
pMintGate transgenes that were introduced at the attP2 site at 68A1-B2, independent of the
fragments being tested. (C) B2.7 drove GFP expression in leading edge (LE) cells and all
tracheal fusion cells, including DB, DT, LT, and GB. (D–F) Enlarged image of the rectangle
shown in C, indicating anti-GFP reactivity overlapping with anti-Dys reactivity in fusion cells
and leading edge; (D) GFP only, (E) Dys only, (F) merge. (G) C1.7 drove GFP expression in
all fusion cells. (H) D1.4 drove GFP expression in CNS brain cells. (I–J) Both E3.8 and F3.8
drove expression in hindgut (HG) and anal pad (AP). There was an absence of expression in
the rectum (rec). This pattern of expression is identical to endogenous dys.
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Reduction of the dys B2.7 fusion cell CRM to a 155 bp fragment. (A) Schematic of the dys
gene and derivative fragments tested in vivo. Fragments labeled G–Q with associated number
indicating kb or bp. Fragments colored green drove fusion cell expression. (B–L) Fragments
H1.0, J544, and N283 had fusion cell and leading edge expression. Fragments O191 and P155
were expressed in only fusion cells. Fragment M269 had weak leading edge expression, and
the other fragments (G1.7, I517, K152, L156, and Q112) had no expression in fusion cells or
leading edge. Arrows indicate fragment-independent ectodermal expression.
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Identification of the dys C1.7 fusion cell CRM. (A) Schematic of the dys gene and fragments
tested. C1.7 is expressed in fusion cells (see Fig. 1). V345 contains 3 TCGTG Dys:Tgo binding
sites, labeled A–C. Two of the TCGTG sites are preceded by AAG. The X over TCGTG-A
and TCGTG-C indicates that those sites were deleted in V345. (B–F) Fragments R900, T523,
and V345 were expressed in all fusion cells, while fragments S832 and U400 were not. (G)
The TCGTG-A and TCGTG-C sites were deleted in V345. GFP expression at wild-type levels
was occasionally observed in DT (white arrowhead), but was generally highly reduced (yellow
arrowheads) or absent. No expression was observed in DB, LT, or GB.
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Mutational analysis of dys P155 fragment identified several sites required for fusion cell
expression. (A) Schematic of P155 showing the conserved sequences (1–7) that were deleted
and assayed for fusion cell expression. (B–H) The Δ1, Δ2, and Δ6 deletions had no effect on
fusion cell expression, whereas the Δ4 and Δ7 deletions abolished expression, and the Δ3 and
Δ5 deletions resulted in GFP expression in only a few DB and DT cells (arrowheads). Arrows
indicate GFP-expressing non-fusion cells. (I,J) Expression of dys (anti-Dys; magenta) in fusion
cells (I; wild-type control) was reduced in (J) pntΔ88 mutant embryos. The gain was increased
in (J) to show that GFP was weakly present (and not absent) in pntΔ88 DT. (K,L) GFP
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expression of dys C1.7 was abolished in a dys1 mutant, whereas expression of dys P155 was
unaffected.
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Two Dys:Tgo sites and Motif 1 sites are required for fusion cell transcription of CG13196. (A)
Schematic of the 3.3 kb genomic region encompassing the CG13196 gene, and fragments
analyzed in vivo. Shown are the three TCGTG sequences, two Motif 1 sequences, and an AAG
sequence adjacent to TCGTG-C. (B–D) The C350 and D92 fragments drove GFP expression
in all fusion cells, whereas fusion cell expression was absent in the B490 transgenic strain. (E–
Y) Shown are DT fusion cells for (E–G) unaltered and (H–Y) altered versions of D92. Both
(H–M) deletion and (N–S) mutation of each TCGTG site abolished fusion cell expression.
Deletion of Motif 1 sites also abolished expression (T–V), whereas deletion of the AAG
sequence adjacent to TCGTG-C had no effect (W–Y).
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Two Dys:Tgo sites are required for fusion cell transcription of CG15252. (A) Schematic of
11.5 kb of DNA surrounding the CG15252 gene. Shown are the 4 TCGTG motifs, 2 Motif 2
sequences, and the AAG motifs adjacent to TCGTG-C and TCGTG-D. (B–D) Fragments A818
and C100 drove GFP expression in DT cells, whereas B270 did not. (E–Y) DT expression of
unaltered (E–G) and (H–Y) altered versions of C100 are shown. Both (H–M) deletion and (K–
P) mutation of each TCGTG abolished DT fusion cell expression. Deletion of both Motif 2
sites (T–V) or both AAG sites adjacent to the TCGTG sites (W–Y) had no effect on DT
expression.
Jiang et al. Page 22














CG13196 C350 fragment has sequences that promote transcription in all fusion cells.
Schematics of (A) CG13196-A350ΔBC:CG15252-C100 and (B) CG15252-
C100ΔCD:CG13196-A350 constructs. (X) indicates that the TCGTG motifs were deleted.
(C,D) Both constructs were expressed in all fusion cells (DT and LT are shown).
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